40 results on '"Ochoa-Bayona, Jose L."'
Search Results
2. Mismatched donor allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations
3. Sequence of novel agents in multiple myeloma: An instrumental variable analysis
4. Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting
5. Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience
6. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma
7. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: A single institutional experience and literature review
8. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma
9. Clinical presentation and outcome of patients with AL amyloidosis requiring salvage therapy.
10. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications
11. Patterns of use of vascular access devices in patients undergoing hematopoietic stem cell transplantation: results of an international survey
12. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
13. Impact of doxycycline on outcomes in AL amyloidosis.
14. Will adding alkylating agent to bortezomib improve survival of newly diagnosed AL amyloidosis patients?
15. Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma
16. Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines
17. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant
18. Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy
19. Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience.
20. Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?
21. A Phase 2 Study of High-Dose Melphalan Plus Bortezomib (Mel/Vel) Conditioning Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
22. Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease
23. Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd
24. Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis
25. Hepatobiliary manifestations of acute myeloid leukemia
26. Allogeneic Hematopoietic Cell Transplantation Using Fludarabine, Melphalan and Bortezomib (Flu/Mel/Vel) Conditioning For Consolidation Of VGPR Or CR In Myeloma
27. A Strong Correlation Between Spot Urine Protein To Creatinine Ratio and 24-Hour Urine Protein Quantification For Proteinuria Assessment In Patients With Plasma Cell Dyscrasia
28. Outcomes of patients with solitary plasmacytomas (SP) in the era of PET imaging and serum-free light chain (sFLC) testing: A single institution experience.
29. Evaluation of spot urine protein to creatinine ratio and 24-hour urine protein quantification for proteinuria in patients with plasma cell dyscrasia.
30. Allogeneic Hematopoietic Cell Transplantation for Consolidation of VGPR or CR In Myeloma
31. Plasmablastic Lymphoma: A Series of 16 Cases with the Largest Collection of 9 HIV-Negative Cases
32. Oral Mucositis Measured by the Oral Mucositis Assessment Scale (OMAS), but Not by the World Health Organization (WHO) Scoring System, Correlates with Nutritional Changes after Autologous Peripheral Blood Stem Cell Transplantation.
33. Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors
34. Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.
35. .
36. Bortezomib salvage followed by a Phase I/ II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
37. .
38. .
39. .
40. Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.